新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 微粒疗法能够修复心脏病所造成组织损伤

微粒疗法能够修复心脏病所造成组织损伤

来源:生物谷 2014-01-19 11:14

2014年1月19日讯 /生物谷BIOON/ --最近来自澳大利亚悉尼大学和Northwestern Medicine公司的研究人员在期刊Science Translational Medicine,发表了一项研究成果。他们利用一种免疫修饰的微粒材料成功修复了在心脏病发作后心脏组织因炎症而受到的损伤。研究人员发现当注射这种微粒后,在动物模型上,动物心脏组织的损伤降低了50%之多。负责这一研究的Daniel Getts介绍说目前市场上还没有一种产品针对这种心肌梗死之后的炎症反应的药物。

这一微粒本质上是基于一种可生物降解的聚乳酸聚酯研发而成,这一材料也已经被FDA通过,广泛应用于医疗领域。研究人员通过对这一微粒进行修饰,使其表面带上负电,这样微粒就能结合炎症单核细胞并将其输送至脾脏,从而避免在心脏受损部位富集炎症单核细胞导致进一步的损伤并最终达到治疗效果。不过研究人员同时指出,目前这一研究还处于比较早期阶段,距离投入临床还有一段距离。(生物谷Bioon.com)

详细英文报道:

A microparticle therapy developed by researchers at Northwestern Medicine and the University of Sydney in Australia may be able to restore heart tissue damaged by inflammation following a heart attack.

In a study published Jan. 15 in Science Translational Medicine, a new therapy called immune-modifying microparticles, developed by Cour Pharmaceutical Development, reduced heart lesions by 50% in an animal model if injected within 24 hours following a heart attack. When the microparticles were injected into the bloodstream, the heart was able to pump significantly more blood.

"There is nothing on the market today that specifically addresses the inflammatory effects of myocardial infarction," Daniel Getts, Cour's chief scientific officer, told FierceBiotech Research in an interview. Getts is a visiting researcher at Northwestern and cofounded the company in 2013.

Originally discovered by scientists at the University of Sydney, the particles are patented compositions based on a biodegradable, FDA-approved substance called poly (lactic-co-glycolic) acid, which is currently used in a range of therapeutics.

Cour's microparticles are bioengineered to have a negative charge on their surface, which binds them to the positively charged damaging cells--inflammatory monocytes--after the microparticles are injected.

"The particles work by binding to monocytes in the blood and diverting them to the spleen so they're not able to get to the site of inflammation," Getts explained.

When the monocytes bond to the microparticles, a signal on the monocyte that initiates cell death and disposal is activated. This signal guides the inflammatory cells to the spleen, the natural path for the removal of dying cells. The monocytes are disposed, which reduces inflammation and promotes tissue repair.

Though the results are early, Cour's technology could pave the way for new immune-modulating drugs, which help stabilize an underactive or overactive immune system. The problem with current immunomodulators is that they either suppress or stimulate the whole immune system. With the former, the danger is that a suppressed immune system can leave the body susceptible to disease and infection. On the other hand, drugs like antiretrovirals that stimulate the immune system can be toxic because they release synthetic molecules into the body over a prolonged period of time. Getts says Cour's experimental therapy is different because it acts on the inflammatory monocytes while allowing other immune responses to go on unaltered.

The FDA has granted Cour an orphan drug designation for its microparticles for the treatment of acute encephalitis syndrome, an inflammatory disorder of the brain. Cour is also developing microparticles programmed with precise proteins to treat other inflammatory diseases, like Type 1 diabetes, celiac disease and multiple sclerosis.

Cour has already formed partnerships with two large, unnamed pharmaceutical companies for inflammatory diseases, and the startup hopes to begin Phase I and Phase II trials by 2015.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库